Anti-CD100 antibodies and methods of using the same
View Patent ↗Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
1. A method for treating a cancer in an animal in need of treatment, comprising administering to said animal a composition comprising: an isolated antibody or antigen-binding fragment thereof that specifically binds to CD100, wherein the antibody or fragment thereof comprises a VH polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences comprising SEQ ID NOs: 6, 7, and 8, respectively, and a VL polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences comprising SEQ ID NOs: 14, 15, and 16, respectively; and a pharmaceutically acceptable carrier.
2. The method of claim 1 wherein said antibody or fragment thereof inhibits CD100 binding to a CD100 receptor.
3. The method of claim 2 , wherein said CD100 receptor is Plexin-B1.
4. The method of claim 1 , wherein said animal is a mammal.
5. The method of claim 4 , wherein said mammal is a human.
6. The method of claim 1 , wherein the VH of said antibody or antigen-binding fragment thereof comprises the amino acid sequence SEQ ID NO: 9 or SEQ ID NO: 10.
7. The method of claim 1 , wherein the VL of said antibody or antigen-binding fragment thereof comprises the amino acid sequence SEQ ID NO: 17 or SEQ ID NO: 18.
8. The method of claim 1 , wherein the VH and VL of said antibody or antigen-binding fragment thereof comprise the amino acid sequences SEQ ID NO: 9 and SEQ ID NO: 17, respectively, or SEQ ID NO: 10 and SEQ ID NO: 18, respectively.
9. The method of claim 1 , wherein CD100 is expressed by the cancer cells, by inflammatory cells present in a tumor microenvironment, or both.
10. The method of claim 1 , wherein the cancer is head and neck cancer, prostate cancer, colon cancer, breast cancer, lung cancer, or any combination or metastases thereof.
11. The method of claim 1 , wherein antibody or antigen-binding fragment thereof is administered in combination with another cancer therapy, wherein the other cancer therapy is chemotherapy, radiation therapy, anti-cancer antibody therapy, small molecule-based cancer therapy, or vaccine/immunotherapy-based cancer therapy.